Abstracts tagged "Biologicals"

Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Miriam Retuerto Guerrero², Judit Font-Urgelles³, Ivette Casafont-Solé³, Adrián Mayo-Juanatey⁴, Juan José Alegre-Sancho⁵, DALIFER FREITES⁶, Cristina Hormigos Martin⁷, Noemí Garrido⁸, GUILLERMO GONZALEZ ARRIBAS⁹, Juan Roberto Miguelez Sanchez¹⁰, Andrea García-Valle¹¹, Marta Ibañez¹², Fernando Lozano Morillo¹³, Ángel García Manzanares¹⁴, Sebastián Sandoval-Moreno¹⁵, Josefina Cortés-Hernández¹⁶, Deseada Palma-Sanchez¹⁷, LETICIA LOJO-OLIVEIRA¹⁸, Evelin Cervantes¹⁹, Paz Collado Ramos²⁰, cristina arciniega Larios²¹, Luis Sala²², Eztizen Labrador-Sánchez²³, Cilia Peralta-Ginés²⁴, Nahia Plaza-Aulestia²⁵, Irati Urionaguena Onaindia²⁶, Miguel Medina Malone²⁷, Jose Rosas Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrian³⁰, Fred Anton Pages³¹, Jose Ramón Lamua-Riazuelo³², María Dolores Fábregas Canales³³, María José Alados Hernández³⁴, Marta Garijo Bufort³⁵, Anna Pamies³⁶, Luis Sarabia³⁷, Rodrigo Aguirre-del-Pino³⁸, José Ángel Cabezas Lefler³⁹, alvaro seijas³⁸, Carmen Carrasco-Cubero⁴⁰, Ana López-Cerón Cofiño⁴¹, Vera Ortiz-Santamaria⁴², Santos Castañeda⁴³, Maria Laino⁴⁴, Carmen Ordás Calvo⁴⁵, Celia arconada⁴⁶, ana Urruticoechea-Arana⁴⁷, Blanca Garcia-Magallon⁴⁸, Ana Valeria Acosta Alfaro⁴⁹, Samuel Leal Rodriguez⁵⁰, Marina Salido Olivares⁷, Patricia Lavilla Villar⁵¹, Anahy Maria Brandy³, Inmaculada Ros Vilamajo⁵², Alvaro García Martos⁵³, Berta Magallares⁵⁴, Guillen Sada Urmeneta⁵⁵, Cristina Córdoba Martín⁵⁶, Elena Riera Alonso⁵⁷, Carmen Bejerano-Herreria⁵⁸ and Ricardo Blanco,<58, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁰Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, ¹¹Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ¹³Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, ¹⁴Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁵Hospital Universitario Vall D'Hebron, Barcelona, Spain, ¹⁶Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁷Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁹Hospital Provincial de Pontevedra, Pontevedra, Spain, ²⁰Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ²¹Hospital de Mérida, Badajoz, Spain, ²²Hospital Universitario de Torrejón, Madrid, Spain, ²³Hospital General de La Rioja, Logroño, Spain, ²⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁵Hospital Galdakao, Vizcaya, Spain, ²⁶Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ²⁷Hospital de Calahorra, Calahorra, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁹Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁰Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ³¹Hospital General de Segovia, Segovia, Spain, ³²Hospital Universitario del Henares, Madrid, Spain, ³³Hospital de Barbastro, Huesca, Spain, ³⁴Hospital Universitario Puerta del Mar, Cadiz, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, ³⁷Complejo Hospitalario de Jaén, Jaén, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Complejo Asistencial de Zamora, Zamora, Spain, ⁴⁰Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴¹Hospital Santa Bárbara, Soria, Spain, ⁴²Hospital General de Granollers, Barcelona, Spain, ⁴³Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁵Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁴⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴⁸Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴⁹Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ⁵⁰Hospital Universitario La Fe, Valencia, Valencia, Spain, ⁵¹Hospital General de Villalba, Collado Villalba, Madrid, Spain, ⁵²Hospital Son Llàtzer, Palma de Mallorca, Spain, ⁵³Hospital del Tajo, Aranjuez, Madrid, Spain, ⁵⁴Hospital de Sant Pau, Barcelona, Spain, ⁵⁵Rheumatology, Hospital Reina Sofía, Tudela, Spain, ⁵⁶Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, ⁵⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁵⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…
Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Elodie Portier¹, Olivier Fogel², Terkia Medkour³, Sophie Hecquet³ and Jérôme AVOUAC³, ¹Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, ²AP-HP, Paris, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
Abstract Number: 1065 • ACR Convergence 2025
Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis
Jiha Lee¹, Sofia Pedro² and Kaleb Michaud³, ¹University of Michigan, Ann Arbor, MI, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Older age is a recognized risk factor for serious infection (SI) associated with anti-TNF therapy in rheumatoid arthritis (RA). Among older adults with RA,…
Abstract Number: 0577 • ACR Convergence 2025
Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Laure Gossec¹, Mohamed Sharaf², Xenofon Baraliakos³, mitsumasa kishimoto⁴, Ruben Queiro⁵, Ennio Lubrano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Enrique R. Soriano¹⁰, Proton Rahman¹¹, Frank Behrens¹² and Stefan Siebert¹³, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Kyorin University School of Medicine, Tokyo, Japan, ⁵Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ⁶Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹¹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹²Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ¹³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Randomized controlled trials have demonstrated the efficacy of IL-23 inhibitors (i) and IL-17i in PsA; however, real-world data on their effectiveness in heterogeneous patient…
Abstract Number: 0790 • ACR Convergence 2025
Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data
Arjun Mahajan¹, David Bates², Vinod Nambudiri³, Avery LaChance², Jeffrey Sparks⁴ and Evan Piette³, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis is a chronic inflammatory skin disease associated with increased risk of metabolic complications, such as diabetes mellitus. However, the impact of specific biologic…
Abstract Number: 0476 • ACR Convergence 2025
Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Maxim Korolev¹, Alexander Dubikov², Daria Bukhanova³, Alina Egorova³, Eugenyi Alekseev⁴, Sofia Kuzkina⁵ and Mikhail Samsonov³, ¹Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia, ²Rheumatology clinic of Professor Dubikov A.I., Vladivostok, Russia, ³R-Pharm JSC, Moscow, Russia, ⁴"R-Pharm", JSC, Moscow, Russia, ⁵R-Pharm, Moscow, Russia
Background/Purpose: Comorbidities may affect the efficacy of bDMARDs in rheumatoid arthritis (RA). Post-hoc analysis of the randomized clinical trial (RCT) data shows that the efficacy…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 2610 • ACR Convergence 2025
Imaging remission in aortitis associated with giant cell arteritis. Multicenter study with tocilizumab in monotherapy and combined therapy
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Aortitis is a frequent and potential severe complication of giant cell arteritis (GCA)(GCA-aortitis). Tocilizumab (TCZ) was approved for the treatment of GCA, but its…
Abstract Number: 2450 • ACR Convergence 2025
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Irene Carrión-Barberà¹, Tarek Salman Montes², Laura Triginer³, Judit Font-Urgelles⁴, Anne Riveros frutos⁵, Sandra Garrote Corral⁶, Maria Garcia-Villanueva⁷, Carlos de Frías Polo⁸, María Galindo-Izquierdo⁹, Berta Magallares¹⁰, Andrea Hernández-martín¹¹, Jorge Juan Fragío Gil¹², Sebastián Sandoval Moreno¹³, Consuelo Ramos Giraldez¹⁴, Josefina Cortés-Hernández¹⁵, Elvira Díez García¹⁶, Clara Moriano¹⁷, Paloma Vela Casasempere¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Irene Altabás-González²⁰, Samuel Hernández-Baldizón²¹, Leyre Riancho²², Inmaculada Ros Vilamajo²¹, Carlos Marras Fernández-Cid²³, Maria Piqueras García²⁴, Angel Garcia-Aparicio²⁵, marta Garijo Bufort²⁶, José Gomez-Puerta²⁷, Beatriz Frade Sosa²⁸, Silvia García Cirera²⁹, Vicenç Torrente-Segarra³⁰, Luis Sala³¹, Concepción Fito-Manteca³², Natividad del Val del amo³³, Julia Martínez Barrio³⁴, Jose Rosas Gómez de Salazar³⁵, Sergi Heredia³⁶, ana Urruticoechea-Arana³⁷, Anahy Maria Brandy³⁸, Maria Esther Uriarte³⁹, José María Pego-Reigosa⁴⁰ and Iñigo Rúa-Figueroa⁴¹, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Ramón y Cajal, Madrid, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario ¹² de octubre, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Bareclona, ¹¹Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ¹²Hospital General Universitario, Valencia, Spain, ¹³Hospital Universitario Vall d’Hebron, Barcelona, Spain, ¹⁴Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁵Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁶Complejo Asistencial Universitario de León, León, Spain, ¹⁷Hospital León, LEON, Castilla y Leon, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain, ²¹Hospital Son Llàtzer, Palma de Mallorca, Spain, ²²Hospital de Sierrallana, Torrelavega, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Servicio Murciano de Salud, Murcia, Spain, ²⁵Hospital Universitario de Toledo, Toledo, Spain, ²⁶Rheumatology Department, Hospital de Sagunto, Spain, Valencia, Spain, ²⁷Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²⁸Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁹Consorci Coporació Sanitaria Parc Taulí, Sabadell, Spain, ³⁰Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ³¹Hospital Universitario de Torrejón, Madrid, Spain, ³²Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, ³³Complejo Universitario de Navarra, Navarra, Spain, ³⁴Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ³⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ³⁶Hospital Moisès Broggi, Barcelona, Spain, ³⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁸Hospital Germans Trias i Pujol, Badalona, Spain, ³⁹Hospital Universitario Donostia, San Sebastian, Spain, ⁴⁰Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain
Background/Purpose: Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 1921 • ACR Convergence 2025
Re-escalation of Treatment in Older Adults with Rheumatoid Arthritis After Anti-TNF Therapy De-escalation
Jiha Lee¹, Jonathan Martindale², Una Makris³ and Julie Bynum², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with rheumatoid arthritis (RA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs), including anti-TNFs, are at an increased risk of adverse effects. Current…
Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Susan Manzi¹, Ian Bruce², Eric Morand³, Richard Furie⁴, Yoshiya Tanaka⁵, Patricia Puzio⁶, Emon Khan⁷, Jenny Wissmar⁸, Michael Song⁹ and Catharina Lindholm¹⁰, ¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁴Division of Rheumatology, Northwell Health, Great Neck, NY, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, ¹⁰BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Vassiliki Poulia¹, Eleni Sampatakaki², Dimitrios Katsifis-Nezis³, Maria Pappa³, Evangelia Mole⁴, Sousana Gazi⁴, Elpida Skouvaklidou⁵, Nikolaos Kougkas⁵, Maria Polyzou⁶, Loukia Koutsogeorgopoulou⁶, Ioannis Xynogalas⁷, Anastasios Karamanakos⁷, Konstantinos D Vassilakis¹, Evangelos Papadimitriou⁸, Charalampos Papagoras⁸, Gerasimos Evangelatos⁹, Nafsika Gerolymatou¹⁰, Paraskevi V Voulgari¹⁰ and George E Fragoulis¹, ¹First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ²Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ³Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁴Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁵⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ⁶Department of Pathophysiology, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁷Department of Rheumatology, Evangelismos General Hospital, Athens, Attiki, Greece, ⁸First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece, ⁹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…

« Previous Page
1
…
8
9
10
11
12
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].